< Back to search
Filter
1

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

for
High Risk Myelodysplastic Syndrome,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT03214562

Phase1, Phase2, Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

for
Acute Myeloid Leukemia,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 12+

Code: NCT03589729

Phase2, Recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

for
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70

Code: NCT06287944

Phase1, Recruiting

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

for
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Location: The Bronx NY, Houston TX
Sponsor: Montefiore Medical Center

Sex: All

Age: 18+

Code: NCT05986240

Phase1, Recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

for
Relapsed Myelodysplastic Syndrome,
Location: Nashville TN, Memphis TN
Sponsor: Vanderbilt-Ingram Cancer Center

Sex: All

Age: 18+

Code: NCT06399640

Phase1, Recruiting

Interested in new myelodysplastic syndromes trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

IS-free Treg HaploHCT

for
Stem Cell Transplant Complications, Graft Vs Host Disease,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18 - 70+

Code: NCT04678401

Phase1, Recruiting

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

for
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Location: Miami FL, Gainesville FL, Westwood KS, Los Angeles CA
Sponsor: Mateon Therapeutics

Sex: All

Age: 18+

Code: NCT02576301

Phase1, Phase2, Recruiting

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

for
Myelodysplastic Syndromes
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 70+

Code: NCT05350748

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

for
Acute Myeloid Leukemia, Myelodysplastic Syndromes,
Location: Pittsburgh PA, Tampa FL, Milwaukee WI, Houston TX
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT04771130

Phase1, Phase2, Recruiting

Registry of Older Patients With Cancer

for
Chronic Myeloproliferative Disorders,
Location: Morehead City NC, New Bern NC, Greenville NC,
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 65+

Code: NCT01137825

Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

for
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04239157

Phase2, Recruiting

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

for
Acute Myeloid Leukemia, Myelodysplastic Syndrome,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05010122

Phase1, Phase2, Recruiting

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

for
Fanconi Anemia, Severe Marrow Failure,
Location: Cincinnati OH, Seattle WA
Sponsor: Children's Hospital Medical Center, Cincinnati

Sex: All

Age: 0+

Code: NCT02143830

Phase2, Recruiting

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

for
Acute Myeloid Leukemia,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT06357182

Phase1, Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

for
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma,
Location: Jacksonville FL, Grand Forks ND
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT05969860

Phase2, Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

for
Myelodysplastic Syndromes (MDS), Beta-thalassemia,
Location: Los Angeles CA
Sponsor: Celgene

Sex: All

Age: 18+

Code: NCT04064060

Phase3, Recruiting

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

for
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70+

Code: NCT06498973

Phase1, Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

for
Acute Myeloid Leukemia,
Location: Boston MA, Cleveland OH, Houston TX, Portland OR
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT03471260

Phase1, Phase2, Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

for
Recurrent Acute Myeloid Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT04375631

Phase1, Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

for
Monoclonal Gammopathy of Undetermined Significance (MGUS),
Location: Weymouth MA, Boston MA, Brighton MA, Methuen MA,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT02269592

Recruiting